Gedatolisib could “establish a new standard of care” for PIK3CA-mutated breast cancer, an investigator said, but the results nonetheless appeared to disappoint investors.
Gedatolisib triplet achieved mPFS 11.1 months vs 5.6 months with alpelisib/fulvestrant (HR 0.50; P<.0001), meeting the primary endpoint in a post-CDK4/6 inhibitor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results